Deletions in the fifth alpha helix of HIV-1 matrix block virus release  by Sanford, Bridget et al.
Deletions in the ﬁfth alpha helix of HIV-1 matrix block virus release
Bridget Sanford a,1, Yan Li a,1, Connor J. Maly a, Christian J. Madson a, Han Chen b,
You Zhou b,c, Michael Belshan a,c,n
a Department of Medical Microbiology and Immunology, Creighton University, 2500 California Plaza, Omaha, NE 68178, USA
b Center for Biotechnology, University of Nebraska-Lincoln, Lincoln, NE, USA
c Nebraska Center for Virology, Lincoln, NE, USA
a r t i c l e i n f o
Article history:
Received 27 May 2014
Returned to author for revisions
15 June 2014
Accepted 18 August 2014







a b s t r a c t
The matrix (MA) protein of HIV-1 is the N-terminal component of the Gag structural protein and is
critical for the early and late stages of viral replication. MA contains ﬁve α-helices (α1–α5). Deletions in
the N-terminus of α5 as small as three amino acids impaired virus release. Electron microscopy of one
deletion mutant (MAΔ96-120) showed that its particles were tethered to the surface of cells by
membranous stalks. Immunoblots indicated all mutants were processed completely, but mutants with
large deletions had alternative processing intermediates. Consistent with the EM data, MAΔ96-120
retained membrane association and multimerization capability. Co-expression of this mutant inhibited
wild type particle release. Alanine scanning mutation in this region did not affect virus release, although
the progeny virions were poorly infectious. Combined, these data demonstrate that structural ablation of
the α5 of MA inhibits virus release.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Human immunodeﬁciency virus type 1 (HIV-1) is a member of
the lentivirus subfamily of the Retroviridae family and the etiologic
agent of acquired immune deﬁciency syndrome (AIDS). Similar to
all retroviruses, HIV-1 has 3 major genes, gag, pol and env. The gag
gene produces a polyprotein precursor Pr55Gag (Gag) that mediates
the essential steps in virus assembly including plasma membrane
binding, incorporation of the genomic RNA, multimerization and
particle formation, and recruitment of the host endosomal sorting
complex required for transport (ESCRT) pathway for release of the
particles (Freed, 1998). During or shortly after budding, Gag is
proteolytically cleaved by the viral protease into the four major
structural proteins: matrix (MA), capsid, nucleocapsid, p6; and the
two spacer proteins p1 and p2. This cleavage is required for efﬁcient
release of particles from cells (Kaplan et al., 1994). The MA protein is
comprised of 132 amino acids and makes up the N-terminal subunit
of the Gag polyprotein (Fiorentini et al., 2006). NMR and crystal-
lography show that MA contains ﬁve alpha helices, the ﬁrst four of
which form an N-terminal globular head and the ﬁfth (α5), located
at the C-terminus, projects away from the head beginning at amino
acid 96 (Hill et al., 1996; Massiah et al., 1996).
MA plays important roles in both entry and egress stages of the
viral lifecycle. During the early steps of replication, MA is asso-
ciated with reverse transcription complexes (RTCs) and preinte-
gration complexes (PICs) (Fassati and Goff, 2001; Gallay et al.,
1995). Stemming from this observation, it was proposed that MA is
involved in virus uncoating and PIC nuclear import (Haffar et al.,
2000; Kaushik and Ratner, 2004). MA contains one nuclear export
signal and two transferable nuclear localization signals, one in the
N-terminus and one in the C-terminus of the protein (Bukrinsky
et al., 1993; Dupont et al., 1999; Haffar et al., 2000). However, the
role of MA during the afferent steps of virus replication remains
controversial. Several studies refute the role of MA in the early
steps of replication and show that mutation of the nuclear
localization signals has no consequence on nuclear import of viral
DNA (Fouchier et al., 1997; Freed et al., 1995; Freed and Martin,
1994; Hearps et al., 2008). Moreover, removal of the C-terminus of
gp41 permits the replication of HIV with a large portion of MA
deleted (Reil et al., 1998).
The production of progeny virions requires assembly of the
viral proteins into immature particles at the plasma membrane
and recruitment of the ESCRT (endosomal sorting complex
required for transport) machinery for particle release (reviewed
in Balasubramaniam and Freed (2011) and others). The MA domain
targets the Gag and Gag-Pol polyproteins to the plasma membrane
and mediates incorporation of the viral envelope protein (ENV).
The ﬁrst 6 amino acids are critical for proper PM targeting via an
N-terminal myristic acid moiety that is added co-translationally to
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the N-terminal glycine residue following the removal of the leader
methionine (Bryant and Ratner, 1990; Freed et al., 1994; Spearman
et al., 1994). In addition of the N-terminus, amino acids 84–88 are
essential for correct targeting of virus assembly to the plasma
membrane (Freed et al., 1994). Numerous single amino acid
substitutions in the N-terminal region of MA (amino acids 11–13,
16, 27–30, 34, 37, 63–65, and 77–80) as well as the beginning of α5
(aa 98–100) abrogate ENV incorporation (Freed and Martin, 1995,
1996; Lee et al., 1997; Murakami and Freed, 2000; Ono et al., 1997;
Yu et al., 1992).
MA α5 includes amino acids 96–121. Previous mutagenesis
studies of this region show effects on both early and late steps of
virus replication. A K98E substitution caused an infectivity defect
at an early post-entry step (Kiernan et al., 1998). Deletion of amino
acids 98–100 abolished ENV incorporation (Dorfman et al., 1994).
This phenotype was also observed with a single A99V substitution
(Brandano and Stevenson, 2011). A related substitution (A99E)
blocks virus production in CEM cells (Freed et al., 1994). Deletions
of amino acids 105–114 or 116–123 exhibit no effect on late events
and a mild impairment on infectivity attributed to decreased
envelope incorporation (Bhatia et al., 2007). However, truncation
of the intracellular tail of the viral transmembrane protein gp41
rescues the ENV incorporation defect (Bhatia et al., 2009).
In this study we investigated a panel of mutants with deletions
within amino acids 96–120 of MA. Viruses containing deletions of
amino acids 96–99 or 100–107 exhibited severely impaired virus
release from cells compared to wild-type. Alanine scanning
mutations in this area did not block release. Deletion of aa
96–120 did not affect Gag multimerization or membrane associa-
tion, and the Gag proteins of all the deletion mutants showed
complete proteolytic processing. Transmission electron microcopy
(TEM) and confocal microscopy of the Δ96-120 mutant showed a
phenotype and pattern of localization similar to a p6 late domain
mutant. However, unlike the late domain mutant, over-expression
of the NEDD4L ubiquitin ligase could not rescue its release. These
results suggest that the deletions in this region create a structural
defect that leads to a release deﬁciency distinct from late domain
mutants.
Results
Deletions within amino acids 96–107 of matrix block virus release
A series of HIV-1 NLX-derived (Brown et al., 1999) molecular
clones were constructed with deletions in α5 of MA (Fig. 1). The
largest clone, MAΔ96-120, had all but a single amino acid of the
C-terminal helix of MA removed. All subsequent deletions were
smaller iterations of this clone for mapping studies (Fig. 1B). We
also constructed a previously described PTAP to LIRL p6 mutant to
use as a control in the release assays (Demirov et al., 2002b).
Initially we investigated whether the deletions affected virus
release. First we examined virus release from transiently trans-
fected 293T cells by immunoblot. Supernatants and cell lysates
were collected and virus particles concentrated by ultracentrifu-
gation through a sucrose cushion. Samples were analyzed by
immunoblot for p24 capsid and MA (Fig. 2A). There was substan-
tially less p24 and MA detected in the supernatants of any mutant
with either amino acids 96–99 or 100–107 deleted, which was
comparable to the PTAP late domain mutant (lane 8). No release of
MAΔ96-120 was observed when supernatants were directly cen-
trifuged either (data not shown). To conﬁrm these data, we also
measured the levels of RT activity present in supernatants by
exogenous RT assay (Fig. 2B). Consistent with the immunoblot
data, only the Δ107-120 mutant exhibited efﬁcient release of virus.
The results were also the same when virus release was measured
by p24 antigen ELISA (data not shown).
Deletions in proteins can cause structural problems. The
proteolytic cleavage site for MA is at aa 132 and to explore the
possibility that the deletions blocked Gag processing we examined
the expression and processing of each mutant in cell lysates
(Fig. 2C). Full length p55 Gag, p24, and MA were detected for all
the mutants, although the level of MA detected varied among the
clones and was consistently low for MAΔ96-99 and MAΔ100-107.
This could suggest a loss of expression of these mutants; alter-
natively, the differences in expression levels might have been due
to loss of antibody detection. The detection of both MA and p24
capsid protein demonstrated that complete protease processing
occurred for each mutant. As expected, the Gag and MA proteins of
the various deletion mutants migrated at different rates reﬂecting
their different amino acid length. The only exception was the p55
Gag protein of MAΔ107-120 which migrated at a larger than
expected size (lane 5). The expected proteolytic cleavage band
p41 was readily detected for all the mutants except Δ96-99 and
Δ100-107 (lanes 6, 7), which both showed lower overall expres-
sion in replicate experiments. Notably, in addition to the expected
slightly smaller p41 intermediate band, a prominent alternative
processing intermediate at 41 kDa was detected in the lysates of
both MAΔ96-120 and MAΔ96-107 (indicated on blot with (n)).
This data suggested that some alternative cleavage occurred with
those mutants during processing. Similar to wild-type NLX,
protease inhibitor treatment of MAΔ96-120 completely blocked
all cleavage, indicating that any aberrant cleavage was not due to
cellular proteases (Fig. 2D).
The virus release data indicated that all of the deletions in MA
would likely block virus replication due to the release defect
except for MAΔ107-120. Nevertheless we measured the infectivity
of MAΔ107-120 to see if the deletion affected virus viability.
Mutant and wild-type virus stocks were produced by transient
transfection of 293T cells and normalized by RT activity. Infectivity
was measured using TZM-bl indicator cells, which showed that
MAΔ107-120 exhibited levels of infection comparable to NLX
(Fig. 2E). This combined with the release data, indicates this region
is dispensible for virus infection in vitro.
Microscopy analysis
To determine the nature of the MAΔ96-120 release defect,
transmission electron microscopy (TEM) was performed on cells
transiently transfected with pNLX or pMAΔ96-120. As reported in
other studies, we observed electron dense sites of the initial
formation of virus particles on the plasma membrane of cells
and only a small number of mature virus particles that appeared to
be released in NLX transfected cell grids (Fig. 3A; (Babe and Craik,
1994; Chrystie and Almeida, 1988; Lee and Linial, 1994; Pal et al.,
1990)). In marked contrast, the MAΔ96-120 cells had clusters of
virus particles accumulated at the plasma membrane of cells
(Fig. 3B–F), suggesting that deletion of amino acids 96–120 caused
a defect in virus budding and release. The clusters of particles
numbered from a few to 450. The MAΔ96-120 particles appeared
to undergo normal formation of electron dense budding sites at
the surface of cells (Fig. 3C–E), and showed no gross change in
morphology.
The notable phenotype observed with the MAΔ96-120 mutant
was the presence of particles connected to cells by large budding
stalks (Fig. 3D and E, black arrows). This suggested that the release
defect was due to a failure of stalk closing and membrane scission.
Stalks were also seen between particles and at sites of clustered
virus particles. Occasionally particles with narrow stalks were also
observed (Fig. 3F, asterisk), but with less frequency. Overall, the
images suggested that the release defect of the MAΔ96-120
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mutant was at a late budding step. To rule out that a protein factor,
such as BST-2/tetherin, was responsible for tethering the particles
to the cells, we performed subtilisin protease release experiments
as described previously (Neil et al., 2006; Van Damme et al., 2008).
In these experiments MAΔ96-120 transfected cells were treated
brieﬂy with subtilisin to release particles attached to cells via
protein bridges. In repeated experiments we failed to detect any
release of viral proteins by immunoblot (data not shown). This
ﬁnding, combined with the fact that 293T cells do not express BST-
2/tetherin (Sato et al., 2009; Van Damme et al., 2008) supports the
supposition that the MAΔ96-120 particles are tethered via the
membrane to cells.
To determine the overall localization pattern of the MAΔ96-120
mutant, we inserted the deletion into the previously described
Gag-EGFP construct (Hermida-Matsumoto and Resh, 2000) and
compared its localization to a wild-type as well as a PTAP mutant
Gag-EGFP by confocal microscopy of transfected HeLa cells. Two
distinct patterns of Gag-EGFP localization were observed in cells
transfected with wild-type Gag-EGFP, diffuse staining or cells full
of distinct puncta (Fig. 4A and B). Quantiﬁcation of the localization
patterns indicated that Gag-EGFP was diffuse in the majority of
cells (Fig. 4G). In contrast, the Δ96-120 mutant showed primarily
punctate localization (Figs 4C and D), very similar to that observed
with the PTAP mutant (Fig. 4E and F). This conclusion was
supported when the localization patterns were counted (Fig. 4G)
– both mutants exhibited a substantial increase in the proportion
of cells with punctate staining. These results, combined with the
TEM and biochemical data, indicate that the deletions in MA result
in a localization phenotype similar to the late domain mutant.
MAΔ96-120 Gag associates with membranes
The inability of the deletion mutants to release from cells could
also result from a loss of other critical functions of MA during virus
assembly or release. MA is required for targeting of Gag to sites of
assembly at the plasma membrane. To test if the deletions in MA
affected this function, we performed membrane ﬂoatation assays.
The lysates of cells expressing MAΔ96-120 or wild-type NLX were
separated into membrane and soluble fractions using step gradi-
ents. Gradient fractions were collected by positive displacement
(fraction 1¼top) and viral proteins detected by SDS-PAGE and
western blot (Fig. 5). Gag protein was detected in fractions 2 and
3 from gradients of NLX transfected cells, indicative of protein
associated with membranes, and in fractions 8 and 9, indicative of
soluble proteins (Fig. 5, bottom panel). The pattern of viral protein
distribution was similar in cells transfected with the MAΔ96-120
mutant (Fig. 5, top panel), indicating the MAΔ96-120 Gag protein
associated with membranes. These data were consistent with the
TEM results.
Co-expression of MAΔ96-120 inhibits wild-type virus release
Another critical step during virus assembly is the multimeriza-
tion of Gag monomers to form immature virus particles. To test
whether MAΔ96-120 Gag was capable of multimerizing, we took
advantage of its size difference with wild-type MA and performed
co-transfection assays to see if MAΔ96-120 could be incorporated
with wild-type Gag and released. To do this, equal amounts of
pNLX and pMAΔ96-120 were transiently transfected into 293T
cells and protein expression and virus release detected by western
blot (Fig. 6A). Both NLX and MAΔ96-120 proteins were detected in
the lysates and supernatants of the co-transfected cells indicating
that MAΔ96-120 multimerized with wild-type Gag were released.
However, as shown in Fig. 6A, the amount of p24 detected in the
supernatants of co-transfected samples was substantially decreased
compared to the NLX sample despite approximately equal amounts
of p24 in cell lysates. From this data, it appeared that expression of
MAΔ96-120 inhibited the release of NLX.
To further test the supposition that MAΔ96-120 was inhibiting
wild-type release, we performed a similar experiment in which a
constant amount of NLX was co-transfected with increasing
amounts of MAΔ96-120 (Fig. 6B). Consistent with the previous
experiment, the amount of capsid and MA released in super-
natants decreased as the amount of MAΔ96-120 increased (top
panels). Examination of the cell lysates showed a slight decrease in
the amount of p55 Gag protein and a slight increase in the amount
of p24 CA. From these experiments we concluded that expression
of MAΔ96-120 inhibits wild-type NLX release in a trans-dominant
manner.
The budding defect of MAΔ96-120 is distinct from late domain
mutants
HIV-1 budding is facilitated by the ESCRT pathway, including
ESCRT-I, –III, Vps4, and ALIX. Recruitment of the ESCRT pathway is
mediated by a late domain present in the p6 region of Gag. This
domain recruits the ESCRT-I component TSG101 to sites of virus
assembly. Mutations in the late domain of HIV Gag impair
membrane scission and show a phenotype similar to that observed
in our EM studies (Carlson et al., 2008; Demirov et al., 2002a;
Fig. 1. MA deletion mutants used in this study. (A) Cartoon depiction of the α-helicies in MA. The position of the amino acids ﬂanking α5 is indicated. (B) Mutants used in this
study. The sequence of amino acids 96–120 of the NLX molecular clone is shown. Names of mutants used in the study are indicated on the left and the amino acids deleted or
mutated are shown on right. Deleted amino acids are denoted with a dash.
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Garrus et al., 2001; Göttlinger et al., 1991; Morita et al., 2011).
Therefore, we next investigated if MAΔ96-120 was able to recruit
ESCRT pathway. First we tested whether the Gag protein of MAΔ96-
120 interacted with endogenous TSG101 by co-immunoprecipitation
assay using the Gag-EGFP constructs. Cells were transfected with
wild-type or MAΔ96-120 Gag-GFP, lysed, and immunoprecipitated
with HIV immunoglobulin. As shown in Fig. 7A, TSG101 co-immuno-
precipitated with both wild-type and MAΔ96-120 Gag-EGFP, indicat-
ing that the mutant was capable of interacting with TSG101.
Previous studies have also shown that over-expression of ALIX
or the HECT domain E3 ubiquitin ligase NEDD4L can rescue
budding of p6 late domain mutants, (Chung et al., 2008; Fisher
et al., 2007; Usami et al., 2007, 2008). The mechanism is not
completely understood although recent data shows that Gag
ubiquitination is required for virus release (Sette et al., 2013). To
further test if the MAΔ96-120 defect was related to the defect seen
with p6 late domain mutants, we assessed whether the over-
expression of NEDD4L could rescue its release. The molecular
clones (NLX, MAΔ96-120, or NLX-PTAP) were co-transfected with
a NEDD4L expression vector and virus release monitored by
western blot analysis of supernatants as in previous experiments
(Fig. 7B). Despite the fact that NEDD4L over-expression was able to
facilitate release of the PTAP mutant (top panel, compare lanes 8–4),
the release of MAΔ96-120 was still blocked (lane 7). These results
suggested that the defect caused by the deletion in MA was distinct
from that observed with p6 late domain mutants.
Fig. 2. Expression and release of MA deletion mutants. (A) Virus release. Supernatants were collected from 293T cells transiently transfected with the HIV-1 clones indicated
at the top and directly resolved by SDS-PAGE. The indicated viral proteins detected by western blot. All blots are representative of at least three independent experiments.
(B) Reverse transcriptase activity released from cells. Supernatants were assayed by in vitro [32P]–TTP incorporation assay. Error bars show standard error of triplicate
experiments. (C) Immunoblot of cell lysates. Gag products were detected with HIV Ig (top panel). Aberrant processing intermediates are indicated with a (*). (D) Effects of
Lopinavir treatment. Supernatants were collected from 293T cells transiently transfected with the HIV-1 clones and directly resolved by SDS-PAGE and immunoblotted to
detect release (top panel). Lower panels show immunoblots of cell lysates. (E) Infectivity of MAΔ107-120. Virus stocks were normalized by RT activity and infectivity
measured using TZM-bl indicator cells. The results were normalized relative to wild-type NLX. Data represents the mean of three independent experiments and the error
bars denote the combined SEM of all experiments.
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Amino acid mutagenesis does not block release
Finally, to test the supposition that structural ablation was
causing the release defect we constructed three alanine scanning
mutants within amino acids 100–107 (Fig. 1B). Notably, immuno-
blot of cell lysates and superantants showed that all three mutants
were readily expressed and released from cells (Fig. 8A and B).
These data support the theory that deletions in α5 of MA cause
a structural ablation and result in an inhibition of virus release.
The viruses were then tested for infectivity on TZM-bl cells
(Fig. 8C). All three mutants showed a loss of infectivity, indicating
that this region of MA is important for the afferent steps of virus
replication.
Discussion
The HIV-1 MA protein plays important roles in both early and
late stages of the viral lifecycle (Fiorentini et al., 2006; Freed, 1998;
Ghanam et al., 2012). The experiments described herein show that
deletions in the N-terminal portion of the 5th alpha helix of the
MA protein impair virus release. Mutants lacking either amino
acids 96–99 or 100–107 showed a reduction in virus production
compared to wild-type NLX. Moreover, co-expression of MAΔ96-
120 blocked wild-type virus release in a trans-dominant manner.
Notably, despite a 13 amino acid closer to the MA–CA cleavage site
(amino acids 107–120) did not appreciably affect virus egress. TEM
of MAΔ96-120 showed fully formed particles tethered to cells by
Fig. 3. Transmission electron microscopic images showing viral particles in the surface regions of cells expressing wild-type NLX (A) and MAΔ96-120 (B-F). Arrows indicate
visible membrane stalks. Scale bars: 0.1 mm.
Fig. 4. Localization of Gag-GFP constructs. (A) Confocal microscopy of HeLa cells transiently transfected with wild-type (a, b), MAΔ96-120 (c, d), or PTAP mutant Gag-GFP
(e, f) constructs. (G) Graphical representation of observed localizations of proteins.
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membranous stalks. Consistent with this, protease treatment of
cells did not permit release of particles. Moreover, the majority
of these studies were performed with 293T cells which do not
express the restriction factor BST-2/tetherin (Sato et al., 2009; Van
Damme et al., 2008). In contrast to the deletion mutants, site-
directed mutagenesis of this region did not affect release. Com-
bined these data indicate that this region of MA contains structural
elements critical for virus release. To our knowledge, this is the
ﬁrst studies to describe a release defect phenotype associated with
the MA protein.
Efﬁcient virus production requires multiple steps, including
targeting and multimerization of Gag/Gag-Pol polyproteins and
recruitment of the ESCRT pathway. The ﬂoatation experiments and
western blot analysis of transfected cell lysates demonstrated that
MAΔ96-120 is targeted to membranes and proteolytically pro-
cessed. The defect was evident in the TEM analysis. The MAΔ96-
120 viruses formed particles that failed to abscise from the plasma
membrane. This resulted in clusters of viruses present at the cell
surface. The presence of incompletely closed virus particles
(Carlson et al., 2008) and membrane stalks suggests that the
MAΔ96-120 tethering results from a failure of membrane abscis-
sion. The ﬁnal step of virus budding requires recruitment of the
ESCRT-III components including CHMP2A, CHMP4B, and Vps4
(Garrus et al., 2001; Morita et al., 2011), and the ubiquitination
of Gag (Sette et al., 2013). Recruitment of ESCRT is facilitated by
the interaction of the p6 region of Gag with the ESCRT-I compo-
nent TSG101. MAΔ96-120 Gag retained interaction with TSG101
suggesting that ESCRT recruitment is not the cause of the budding
defect. Furthermore, over-expression of NEDD4L, which can com-
pensate late domain mutants, failed to promote release of MAΔ96-
120. Combined these data suggest that the deletions in MA result
in a structural ablation of Gag that impairs budding via a novel
mechanism.
Although the TEM studies showed clusters of virus-like parti-
cles on the surface of cells, the results thus far cannot rule out the
possibility that the deletion of residues 96–120 creates a structural
constraint that mistargets Gag or blocks an essential modiﬁcation
of Gag necessary for processing and/or release. The misfolding of
proteins can lead to the targeting of proteins to the proteosome or
other intracellular structures such as aggresomes or inclusion
bodies. However, healthy mitochondria were seen in MAΔ96-120
transfected cells, we did not observe any intracellular structures
containing virus like particles, nor did we observe any structures
fused to lysosomes, which would be indicative of autophagsome
formation (data not shown). Finally, p24 CA and p17 MA were
observed by immunoblot in both cell-free virus and lysates of
MAΔ96-120 transfected cells. Combined, these results argue
against misfolding or blockage of processing as the mechanism
of release inhibition.
Fig. 5. Membrane ﬂoatation assay showing MAΔ96-120 is associated with mem-
branes. 293T cells were transfected with either MAΔ96-120 (top panel) or wild-
type NLX (bottom panel) for 24 h. Cells were lysed by hypotonic swelling/dounce
homogenization and ultracentrifuged on a sucrose step gradient. Fractions were
collected from the top and analyzed by SDS-PAGE and western blot with anti-Gag
antiserum. Data is representative of two independent experiments.
Fig. 6. Co-expression of MAΔ96-120 and NLX. (A) MAΔ96-120 is capable of multimerization with wild-type NLX. 293T cells were transfected with both NLX and MAΔ96-
120, or either clone alone as indicated at the top. (B) MAΔ96-120 trans-dominantly inhibits wild-type virus release. Cells were transfected transiently with a constant
amount of NLX plasmid, increasing amounts of MAΔ96-120, and pUC19 to normalize the overall amount of plasmid DNA. Supernatant and lysate samples were isolated and
the indicated viral proteins detected as described in Fig. 2 legend. Panels are a representative of three independent experiments.
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Finally, we identiﬁed that the amino acid sequence in this
region was critical for the early steps of virus replication. The Los
Alamos National Laboratory sequence database indicates that with
the exception of E107, amino acids 100–107 (–ALDKIEEE-) are
highly conserved across all virus clades. Two previous studies
investigated deletions in the 5th α-helix of MA. Yu et al. (1992)
found that deletion of amino acids 105–115 moderately impaired
virus replication, whereas deletion of 116–128 was more deleter-
ious. Both mutants exhibited reductions in viral DNA synthesis.
However, Bhatia et al. (2007) saw only a small (3- to 4-fold)
reduction in infectivity upon deletions of amino acids 105–114 or
116–123. They found that the drop in infectivity correlated with a
reduction in envelope incorporation and reduced membrane
fusion (Bhatia et al., 2007). The loss of virus release precluded
testing of the infectivity of the deletion mutants, however the
alanine scanning mutagenesis showed that amino acids 100–107
are critical for the early steps of virus replication. Combined with
all the previous work, our data conﬁrms that C-terminal α-helix of
MA plays a critical role during the afferent steps of virus replica-
tion. Identiﬁcation of the function(s) of MA during virus infection
could lead to the development of novel inhibitors.
Materials and methods
Cell lines
293T, HeLa, and TZM-bl cells were grown in Dulbecco's
modiﬁed Eagle's medium (DMEM) supplemented with 10% Fetal
Clone III (Hyclone, Logan, UT USA), and 100 U/ml penicillin and
100 mg/ml streptomycin. All cells were grown at 37 1C with a 5%
CO2 atmosphere.
DNA constructs
Deletions in MA and p6 as well as the alanine substitutions
were made in the pNLX clone (Brown et al., 1999) of HIV-1 or
pGag-EGFP (Hermida-Matsumoto and Resh, 2000) using standard
cloning techniques. Brieﬂy, the deletions and substitutions in the
MA regionwere constructed by PCR overlap mutagenesis spanning
the unique BssHII and SpeI restriction sites within gag, whereas the
PTAP to LIRL mutation in p6 was made using the unique SpeI and
SbfI restriction sites. For the Gag-EGFPΔ96-120 and Gag-EGFP-
PTAP clones the restriction sites utilized were BamHI and KpnI.
A list of primers can be provided upon request. The deletion
fragments were gel puriﬁed, digested, and ligated into pNLX cut
with the same enzymes. The complete region inserted into each
clone was veriﬁed by DNA sequencing at the Molecular Biology
Core at Creighton University Medical Center. The NEDD4L expres-
sion construct was obtained from ATCC (Manassas, VA USA).
Virus production and puriﬁcation
Virus stocks were produced by transient transfection of 293T
cells with molecular clones using PEI and puriﬁed as previously
described (Schweitzer et al., 2012). Brieﬂy, supernatants were
collected at 24 h intervals for 3 days, pooled, clariﬁed through a
0.45 μm pore size ﬁlter, aliquoted, and stored at 80 1C. Virus
release was monitored and virus stocks normalized by reverse
transcriptase (RT) assay as previously described (Belshan et al.,
2009). For western blot experiments, supernatants and cells
lysates were collected at 24 h post-transfection. Supernatants
were clariﬁed by centrifugation and virus particles concentrated
by ultracentrifugation through a 20% (w/v in PBS) sucrose cushion.
Lopinavir (1 mM) was added two hours prior to transfection
in indicated experiments. Cells were washed with PBS and lysed
with M-PER lysis buffer as directed by the manufacturer (Pierce
Biotechnology, Rockford, IL). For the NEDD4L rescue experiments,
5 mg of NEDD4L expression plasmid was co-transfected with 10 mg
of molecular clone.
Immunoblots
Cell or viral lysates were resolved by SDS-polyacrylamide gel
electrophoresis and transferred to a PVDF membrane with a semi-
dry blotter. Membranes were incubated for 1 h with the following
primary antibodies: Anti-Gag 1/2000, anti-Matrix 1/2500 (both
kind gifts of Lee Ratner), HIV immunoglobulin 1/20,000 (NIH AIDS
Research & Reference Program) or anti-gp41 Chessie-8 1/1000
((Abacioglu et al., 1994); NIH AIDS Research & Reference Program).
Blots were incubated for 45 min with secondary antibodies con-
jugated with species speciﬁc anti-IgG antibodies conjugated to
horseradish peroxidase. Proteins were detected using SuperSignal
West Pico chemiluminesence substrate (Pierce Biotechnology),
exposed and visualized with ﬁlm. Images were acquired by ﬂat-
bed scanning, cropped, and, if necessary, adjusted for brightness/
contrast.
Fig. 7. The MAΔ96-120 phenotype is distinct from late domain mutants. (A) Co-
immunoprecipiation assay showing MAΔ96-120 Gag interacts with TSG101. Cells
transfected with wild-type or MAΔ96-120 Gag-GFP were lysed, immunoprecipi-
tated with HIV IgG, and immmunoblotted for TSG101 and Gag as indicated.
(B) NEDD4L over-expression does not rescue MAΔ96-120 release. The indicated
molecular clones were co-transfected with a NEDD4L expression construct. Super-
natants and lysates were tested for the indicated proteins as described in Fig. 2.
β-actin was detected as a control. Data is representative of two independent
experiments.
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Membrane association assay
293T cells were transfected as described above with either
pNLX or pMAΔ96-120 and at 24 h post-transfection the cells were
collected and pelleted by centrifugation. The pellet was resus-
pended in a complete protease inhibitor cocktail (Calbiochem, La
Jolla, CA, USA) and dounce homogenized. The lysates were treated
with 5 M NaCl and TNE (25 mM Tris–HCl (ph 7.5), 150 mM NaCl,
4 mM EDTA) þ0.5%Tx-100, equilibrated to 73% sucrose (w/v),
loaded onto a sucrose step gradient (85.5%, 65%, 10% w/v) between
85.5% and 65% layers, and ultracentrifuged for 16 h at 167,242g.
Fractions were collected from the tube by positive displacement
using the BioComp Gradient Master system (Fredericton, New
Brunswick, Canada), mixed 1:1 with 2 sample buffer, separated
by SDS-PAGE and analyzed by western blot as described above.
Microscopy
For the TEM experiments HeLa cells were transfected with
either pNLX or pMAΔ96-120 plasmid using GeneJet transfection
reagent by following the manufacturer's protocol (SignaGen
Laboratories, Rockville, MD, USA). At 24 h post transfection the
cells were washed once with PBS, ﬁxed in 2.5% glutaraldehyde/
2.5% paraformaldehyde, and incubated for 1 h at room tempera-
ture then overnight at 4 1C. The cells were scraped from the plates,
embedded and prepared for imaging as previously described
(Rodriguez-Rocha et al., 2013; Wen et al., 2010). For the Gag-GFP
imaging HeLa cells were seeded on glass coverslips at 50%
conﬂuency and transfected the next day with Gag-EGFP, Gag-
EGFP-MAΔ96-120, or Gag-EGFP-PTAP as described above. At 18 h
post-transfection the cells were washed with PBS, ﬁxed with 3.7%
formaldehyde, and mounted onto slides using Prolong Gold anti-
fade reagent with DAPI to stain nuclei (Life Technologies, Grand
Island, NY). Confocal microscopy was performed in the Creighton
University Microscopy core facility using a Zeiss LSM 510 META
NLO confocal scanning system. Images were cropped and pro-
cessed for brightness/contrast using Adobe Photoshop (Adobe
Systems Inc., San Jose, CA USA).
Infectivity assays
TZM-bl cells were seeded at 2105 cells per well in 24-well
plates. Triplicate wells were inoculated with equivalent amounts
of virus and incubated for 48 h. Mock infections were performed
in parallel as negative controls. Cells were lysed with M-PER lysis
buffer and luminescence measured with a luminometer using
One-Glo substrate as directed by the manufacturer (Promega,
Madison, WI). The results were normalized to the average of the
WT infected samples. Statistical analyses were performed using
Graphpad Prism Software.
Fig. 8. Alanine scanning mutagenesis of MA aa 100-107. Virus expression (A) and release (B) from 293T cells. Proteins were resolved by SDS-PAGE and the indicated viral
proteins detected by western blot. (C) Virus infection of Ala mutants measured on TZM-bl indicator cells. Data is a combination of two independent experiments with
infections performed in triplicate. Error bars denote standard error of the mean; *po0.001 by unpaired two-tail T-test.
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Co-immunoprecipitation
1107 293 T cells were transfected in 10 cm dishes as
described above with either Gag-EGFP or Gag-EGFP-MAΔ96-120.
At 24 h post transfection the cells were lysed with IP lysis buffer
(Tris buffered saline pH 7.8, 1% TritonX-100, 0.5% NP-40, 1
protease inhibitor cocktail). Lysates were pre-cleared with protein
G Sepharose beads (Life Technologies) and rotated overnight at
4 1C with HIV immunoglobulin. The following day protein G
Sepharose beads were added and the samples rotated an addi-
tional 3 h. Beads were washed thrice with IP lysis buffer for
15 min. at 4 1C, pelleted and the captured proteins solubilized by
boiling in 1 sample buffer. Proteins were separated by SDS-PAGE
and analyzed by western blot as described above.
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